Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q2

6523.TEDINET S100S7VD
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥85.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥170.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥89.1bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥2.5bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥10.5bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥8.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥557m2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.4bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥9.7bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥743m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.2bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥8.3bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥733m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥8.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥570.4bnat 2023-09-30Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥596.3bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥423.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥149.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥148.3bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥73.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥5.912023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥9.612022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.62022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥5.882023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥9.522022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥65.982022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.9%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥52.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥51.1bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥9.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-09-30¥55.4bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-09-30¥12.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-09-30¥49.3bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-09-30¥64.8bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥169.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥169.5bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥20.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 914
ItemContextValueUnit
Deferred tax liabilities IFRSCurrentQuarterInstant7284000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant1670000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant1539000000JPY
Non current labilities IFRSPrior1YearInstant292898000000JPY
Non current labilities IFRSCurrentQuarterInstant289164000000JPY
Liabilities IFRSPrior1YearInstant422740000000JPY
Liabilities IFRSCurrentQuarterInstant423400000000JPY
Share capital IFRSPrior1YearInstant47946000000JPY
Share capital IFRSCurrentQuarterInstant48327000000JPY
Capital surplus IFRSPrior1YearInstant43641000000JPY
Capital surplus IFRSCurrentQuarterInstant41851000000JPY
Retained earnings IFRSPrior1YearInstant17081000000JPY
Retained earnings IFRSCurrentQuarterInstant10730000000JPY
Treasury shares IFRSPrior1YearInstant-568000000JPY
Treasury shares IFRSCurrentQuarterInstant-568000000JPY
Other components of equity IFRSPrior1YearInstant29906000000JPY
Other components of equity IFRSCurrentQuarterInstant47036000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant138008000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant147377000000JPY
Non controlling interests IFRSPrior1YearInstant819000000JPY
Non controlling interests IFRSCurrentQuarterInstant-335000000JPY
Equity IFRSPrior1YearInstant138827000000JPY
Equity IFRSCurrentQuarterInstant147042000000JPY
Liabilities and equity IFRSPrior1YearInstant561567000000JPY
Liabilities and equity IFRSCurrentQuarterInstant570443000000JPY
Revenue IFRSPrior1YTDDuration170584000000JPY
Revenue IFRSCurrentYTDDuration166819000000JPY
Cost of sales IFRSPrior1YTDDuration89580000000JPY
Cost of sales IFRSCurrentYTDDuration91728000000JPY
Gross profit IFRSPrior1YTDDuration81003000000JPY
Gross profit IFRSCurrentYTDDuration75090000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration70816000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration71390000000JPY
Other income IFRSPrior1YTDDuration1196000000JPY
Other income IFRSCurrentYTDDuration2989000000JPY
Other expenses IFRSPrior1YTDDuration577000000JPY
Other expenses IFRSCurrentYTDDuration2368000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-265000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-138000000JPY
Operating profit loss IFRSPrior1YTDDuration10540000000JPY
Operating profit loss IFRSCurrentYTDDuration4182000000JPY
Finance income IFRSPrior1YTDDuration134000000JPY
Finance income IFRSCurrentYTDDuration463000000JPY
Finance costs IFRSPrior1YTDDuration7280000000JPY
Finance costs IFRSCurrentYTDDuration7675000000JPY
Profit loss before tax IFRSPrior1YTDDuration3395000000JPY
Profit loss before tax IFRSCurrentYTDDuration-3030000000JPY
Income tax expense IFRSPrior1YTDDuration1955000000JPY
Income tax expense IFRSCurrentYTDDuration-614000000JPY
Profit loss IFRSPrior1YTDDuration1440000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass